SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:his-15263"
 

Search: onr:"swepub:oai:DiVA.org:his-15263" > Plasminogen binding...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Plasminogen binding inhibitors demonstrate unwanted activities on GABAA and glycine receptors in human iPSC derived neurons

Kristensson, Lisbeth (author)
AstraZeneca, Mölndal, Sweden
Lundin, Anders (author)
Karolinska Institutet,AstraZeneca, Mölndal, Sweden / Karolinska Institutet, Stockholm, Sweden
Gustafsson, David (author)
Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden
show more...
Fryklund, Jan (author)
Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden
Fex, Tomas (author)
Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden
Delsing, Louise (author)
Gothenburg University,Göteborgs universitet,Högskolan i Skövde,Institutionen för biovetenskap,Forskningscentrum för Systembiologi,AstraZeneca, Mölndal, Sweden / the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden,Bioinformatics,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Ryberg, Erik (author)
AstraZeneca, Mölndal, Sweden
show less...
 (creator_code:org_t)
Elsevier, 2018
2018
English.
In: Neuroscience Letters. - : Elsevier. - 0304-3940 .- 1872-7972. ; 681, s. 37-43
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Plasminogen binding inhibitors (PBIs) reduce the risk of bleeding in hemorrhagic conditions. However, generic PBIs are also associated with an increased risk of seizures, an adverse effect linked to unwanted activities towards inhibitory neuronal receptors. Development of novel PBIs serve to remove compounds with such properties, but progress is limited by a lack of higher throughput methods with human translatability. Herein we apply human induced pluripotent stem cell (hiPSC) derived neurons in combination with dynamic mass redistribution (DMR) technology to demonstrate robust and reproducible modulation of both GABAA and glycine receptors. These cells respond to GABA (EC50 0.33 ± 0.18 μM), glycine (EC50 11.0 ± 3.7 μM) and additional ligands in line with previous reports from patch clamp technologies. Additionally, we identify and characterize a competitive antagonistic behavior of the prototype inhibitor and drug tranexamic acid (TXA). Finally, we demonstrate proof of concept for effective counter-screening of lead series compounds towards unwanted GABAAreceptor activities. No activity was observed for a previously identified PBI candidate drug, AZD6564, whereas a discontinued analog, AZ13267257, could be characterized as a potent GABAA receptor agonist.

Subject headings

NATURVETENSKAP  -- Biologi -- Cellbiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Cell Biology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

Drug screening
Dynamic mass redistribution
GABA(A) receptor
Glycine receptor
Pharmacology
hiPSC derived neurons
Bioinformatik
Bioinformatics
INF502 Biomarkers
INF502 Biomarkörer
Drug screening
Dynamic mass redistribution
GABAA receptor
Glycine receptor
hiPSC derived neurons
Pharmacology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view